Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Company News

Aug 29

2024

[NEWS] Hua Medicine Announces 2024 Interim Results

Dorzagliatin (trade name: HuaTangNing (华堂宁®)), world's first dual-acting glucokinase activator (GKA), successfully entered China’s National Reimbursement Drug List for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (the “NRDL”) at the end of 2023. Hua Medicine worked with sales promotion partner Bayer Healthcare Company Limited ("Bayer") and 80 Tier 1 distributors to begin the pharmaceutical market entry in 31 municipalities and provinces in China.

Jun 24

2024

[News] Hua Medicine Announces Potential Effects of the Combination of Dorzagliatin and SGLT-2 Inhibitor at 2024 Annual Scientific Sessions

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that the Company and its wholly-owned subsidiary, Nanjing AscendRare Pharmaceutical Technology Co., Ltd.(AscendRare), presented a number of basic research findings at the 84th American Diabetes Association (ADA) Annual Scientific Sessions.

Jun 17

2024

[News] Hua Medicine will present multiple research results at the 2024 American Diabetes Association (ADA) Annual Scientific Sessions

Hua Medicine (the "Company", HKEx stock code: 2552) announced today that its wholly owned subsidiary Nanjing AscendRare Pharmaceutical Technology Co., Ltd.

Apr 26

2024

[News] Hua Medicine Initiated Phase I Clinical Trial of 2nd Gen GKA in the U.S. and Completed Enrollment of First Patient

Hua Medicine (the "Company", HKEx: 2552.HK) announced that the Company has officially initiated its Phase I clinical trial of its 2nd generation glucokinase allosteric activator (2nd Gen GKA) in the United States, with the successful enrollment of the first patient.

Mar 29

2024

[NEWS] Hua Medicine Announces 2023 Annual Results

The Company has achieved a certain milestone relating to the development of dorzagliatin and received RMB800 million non-refundable milestone payment. Collective cash balance of the Company was RMB1,461 million as of December 31, 2023.

Dec 21

2023

Hua Medicine Announces Submission of Investigational New Drug Application with U.S. FDA

Hua Medicine (HKEx:2552HK) announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for its 2nd generation glucokinase allosteric activator (2nd Gen GKA) to initiate a Phase I randomized, double-blinded, placebo-controlled, single-dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study in subjects with Type 2 diabetes mellitus (T2D) in the United States.

Dec 13

2023

[News] Hua Medicine Announces the Inclusion of Dorzagliatin in the National Reimbursement Drug List (NRDL)

Hua Medicine (the "Company", HKEx: 2552.HK) announced today that HuaTangNing (华堂宁®) (dorzagliatin), its self-developed first-in-class glucokinase allosteric activator (GKA) for diabetes, has been successfully included in China's National Reimbursement Drug List (NRDL) by the National Healthcare Security Administration (NHSA).

Nov 23

2023

[News] Hua Medicine to Present Research Findings at CDS 2023

Hua Medicine (HK:2552) today announced that it will present multiple research findings at the 25th Scientific Meeting of the Chinese Diabetes Society (CDS 2023).

Aug 24

2023

[News]Hua Medicine Announces 2023 Interim Results

Hua Medicine (the "Company", HKEx: 2552) today announces the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2023 (the "Reporting Period").

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(华堂宁®)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.